Nanobiotix (NBTX) has released an update.
Nanobiotix, a biotech firm, reported promising therapeutic results with its lead candidate, NBTXR3, which showed favorable safety and tumor response in cancer patients and is expected to reach several clinical milestones for various cancers in the next 12-18 months. Financially, the company announced a cash position of €66.3 million as of June 2024, sufficient to fund operations into the fourth quarter of 2025, alongside an increase in revenue to €9.3 million compared to the previous year.
For further insights into NBTX stock, check out TipRanks’ Stock Analysis page.
